5 WARNINGS AND PRECAUTIONS
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply. Find out more about the Kindle Personal Document Service.
- Not suitable for individuals with severe heart or liver conditions.
- Always inform your healthcare provider of all medications being taken.
- Follow-up appointments ensure safe and effective use.
To save content items to your account, please confirm that you agree to abide by our usage policies.
| Medication Type | Interaction Effect | Recommended Action |
|---|---|---|
| Nitrates | Severe hypotension | Avoid concurrent use |
| Alpha-blockers | Blood pressure lowering effects | Monitor blood pressure closely |
| CYP3A4 inhibitors | Increased sildenafil levels, risk of side effects | Dose adjustment or caution |
| Other PDE5 inhibitors | Enhanced effects, risk of adverse reactions | Avoid combination |
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.
- Sildenafil 12.5 mg is a lower dose used for mild erectile dysfunction.
- It helps relax blood vessels to increase blood flow.
- Often prescribed when starting treatment or for lighter symptoms.
Find out more about saving content to Google Drive. Sildenafil oral tablet is available as a brand-name drug and as a generic drug.
| Pharmacy Name | Price per Box (10 tablets) | Availability | Comments |
|---|---|---|---|
| PharmaPlus | $8 | Widely available | Discount for bulk purchase |
| MedExpress | $9 | Usually in stock | Generic options available |
| Local Clinic | $12 | Prescription required | Consultation fee may apply |
| Online Pharmacy | $6 | Varies | Ensure reputable source |
Sildenafil comes in three forms: an oral tablet, an oral suspension (liquid), and an injection that’s only given by a doctor.
METHODS AND RESULTS
For current full prescribing information, please visit eugiaus.comAll brands listed are the trademarks of their respective owners and are not trademarks of Eugia Pharma Specialities Limited.Distributed by:Eugia US LLC279 Princeton-Hightstown Rd.E. Windsor, NJ 08520Manufactured by:Eugia Pharma Specialities LimitedHyderabad - 500032India Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use). Inform patients of contraindication of sildenafil with regular and/or intermittent use of organic nitrates. Inform patients that sildenafil is also marketed as VIAGRA for erectile dysfunction. Advise patients taking sildenafil not to take VIAGRA or other PDE-5 inhibitors.
Common Sildenafil Side Effects
Advise patients to seek immediate medical attention for a sudden loss of vision in one or both eyes while taking sildenafil. Such an event may be a sign of NAION. Advise patients to seek prompt medical attention in the event of sudden decrease or loss of hearing while taking sildenafil. These events may be accompanied by tinnitus and dizziness. This product's label may have sildenafil tablet manforce 50 mg been updated. Sildenafil oral tablet is used to treat erectile dysfunction (ED).
- Sildenafil 12.5 mg may be prescribed for pulmonary hypertension as well.
- Dose adjustments may be necessary based on age or medical history.
- Regular medical checkups help monitor treatment effects.
It’s also used to treat pulmonary arterial hypertension (PAH). It comes in the form of a tablet and suspension (liquid). It also comes in an intravenous (IV) form, which is only given by a doctor. Sildenafil oral tablet is available as the brand-name drugs Viagra and Revatio. It’s also available as a generic drug.
| Product | Dosage | Quantity + Bonus | Price | |
|---|---|---|---|---|
| Viagra Generic | 25mg | 270 + 8 Pills | 184.26€ 175.49€ | |
| Viagra Generic | 50mg | 20 Pills | 40.52€ 38.59€ | |
| Kamagra Polo | 100mg | 20 Pills | 83.56€ 79.58€ | |
| Kamagra Polo | 100mg | 180 + 8 Pills | 446.52€ 425.26€ | |
| Viagra Generic | 25mg | 120 + 6 Pills | 125.56€ 119.58€ | |
| Viagra Generic | 100mg | 60 + 4 Pills | 96.36€ 91.77€ | |
| Kamagra Polo | 100mg | 272 + 12 Pills | 622.94€ 593.28€ | |
| Kamagra Polo | 100mg | 12 Pills | 60.21€ 57.34€ | |
| Viagra Generic | 25mg | 60 + 4 Pills | 71.99€ 68.56€ | |
| Viagra Generic | 50mg | 120 + 6 Pills | 129.64€ 123.47€ | |
| Kamagra | 100mg | 360 + 6 Pills | 839.95€ 799.95€ | |
| Kamagra Oral Jelly | 100mg | 21 Sachets | 95.92€ 91.35€ | |
| Viagra Generic | 25mg | 90 + 6 Pills | 105.03€ 100.03€ | |
| Kamagra Oral Jelly | 100mg | 10 Sachets | 54.55€ 51.95€ | |
| Viagra Generic | 50mg | 60 + 4 Pills | 83.93€ 79.93€ | |
| Viagra Generic | 50mg | 360 + 10 Pills | 225.33€ 214.60€ | |
| Viagra Generic | 50mg | 10 Pills | 26.87€ 25.59€ |
Generic drugs usually cost less than the brand-name version.
Frequently asked questions
More than twice as many sildenafil-treated patients (36%) as placebo-treated patients (14%) showed an improvement in at least one functional New York Heart Association (NYHA) class for PAH.Study A1481243 (NCT00323297) - Sildenafil Added to Bosentan Therapy – Lack of Effect on Exercise CapacityA randomized, double-blind, placebo-controlled study was conducted in 103 patients with PAH who were on bosentan therapy for a minimum of 3 months. The PAH patients included those with primary PAH and PAH associated with CTD. Patients were randomized to placebo or sildenafil (20 mg three times a day) in combination with bosentan (62.5 to 125 mg twice a day). The primary efficacy endpoint was the change from baseline at Week 12 in 6-minute walk distance (6MWD). The results indicate that there is no significant difference in mean change from baseline on 6MWD observed between sildenafil 20 mg plus bosentan and bosentan alone.Pediatric use information is approved for Viatris Specialty LLC's, REVATIO (sildenafil).
Dosage for erectile dysfunction (ED)
SUPER-1 (NCT00644605) - Sildenafil monotherapy [20 mg, 40 mg, and 80 mg three times a day] Kaplan-Meier Plot of Time (in Days) to Clinical Worsening of PAH in PACES-1 16 HOW SUPPLIED/STORAGE AND HANDLING Sildenafil injection is supplied as a clear, colorless, sterile, ready to use solution containing 10 mg sildenafil/12.5 mL presented in a single-dose glass vial.Single-Dose Vials in a Carton of 1 NDC 55150-166-13Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].Discard Unused Portion.The vial stopper is not made with natural rubber latex.Sterile, Nonpyrogenic Sildenafil injection is supplied as a clear, colorless, sterile, ready to use solution containing 10 mg sildenafil/12.5 mL presented in a single-dose glass vial. 17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).Inform patients of contraindication of sildenafil with regular and/or intermittent use of organic nitrates.Inform patients that sildenafil is also marketed as VIAGRA for erectile dysfunction. Advise patients taking sildenafil not to take VIAGRA or other PDE-5 inhibitors.Advise patients to seek immediate medical attention for a sudden loss of vision in one or both eyes while taking sildenafil. Such an event may be a sign of NAION.Advise patients to seek prompt medical attention in the event of sudden decrease or loss of hearing while taking sildenafil. These events may be accompanied by tinnitus and dizziness.This product's label may have been updated. In some cases, they may not be available in every strength or form as the brand-name drug. Generic oral tablets are available for both conditions, but the brand-name drugs each treat only one of the conditions.
5.4 Visual Loss
For current full prescribing information, please visit eugiaus.com All brands listed are the trademarks of their respective owners and are not trademarks of Eugia Pharma Specialities Limited. PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 10 mg per 12.5 mL - Container Label PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 10 mg per 12.5 mL - Container-Carton (1 Vial) Published online by Cambridge University Press: 19 October 2021 A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content. 729 - 732Publisher: Cambridge University PressPrint publication year: 2020 PDE5 inhibitors – pharmacology and clinical applications 20 years after sildenafil discovery. Br J Pharmacol 2018;175(13):2554–65.CrossRefGoogle ScholarPubMed Expert Opin Pharmacother 2003;4(3):397–405.CrossRefGoogle ScholarPubMed Accessibility compliance for the HTML of this chapter is currently unknown and may be updated in the future.
Sexual Dysfunction (Related to Antidepressant Use)
To save this book to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle. Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. Viagra: This drug is used to treat ED. With ED, you’re unable to get or maintain an erection.
5.2 Worsening Pulmonary Vascular Occlusive Disease
Placebo-Corrected Change From Baseline in 6-Minute Walk Distance (meters) at Week 12 by Study Subpopulation in SUPER-1: Mean (95% Confidence Interval)Key: PAH = pulmonary arterial hypertension; CTD = connective tissue disease; PH = pulmonary hypertension; PAP = pulmonary arterial pressure; PVRI = pulmonary vascular resistance index; TID = three times daily.SUPER-2 (NCT00159887) Long-term Treatment of PAHIn a long-term follow-up of patients who were treated with sildenafil (n=277), K-M estimates of survival at 1, 2, and 3 years were 94%, 88% , and 79%, respectively. These uncontrolled observations do not allow comparison with a group not given sildenafil and cannot be used to determine the long term-effect of sildenafil on mortality.PACES-1 (NCT00159861) - sildenafil Co-administered with EpoprostenolA randomized, double-blind, placebo-controlled study (PACES-1) was conducted in 267 patients with PAH who were taking stable doses of intravenous epoprostenol. Patients had to have a mean pulmonary artery pressure (mPAP) greater than or equal to 25 mmHg and a pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg at rest via right heart catheterization within 21 days before randomization, and a baseline 6-minute walk test distance greater than or equal to 100 meters and less than or equal to 450 meters (mean 349 meters). Patients were randomized to placebo or sildenafil (in a fixed titration starting from 20 mg to 40 mg and then 80 mg, three times a day) and all patients continued intravenous epoprostenol therapy.At baseline patients had PPH (80%) or PAH secondary to CTD (20%); WHO Functional Class I (1%), II (26%), III (67%), or IV (6%); and the mean age was 48 years, 80% were female, and 79% were Caucasian.There was a statistically significant greater increase from baseline in 6-minute walk distance at Week 16 (primary endpoint) for the sildenafil group compared with the placebo group. The mean change from baseline at Week 16 (last observation carried forward) was 30 meters for the sildenafil group compared with 4 meters for the placebo group giving an adjusted treatment difference of 26 meters (95% CI: 10.8, 41.2) (p = 0.0009).Patients on sildenafil achieved a statistically significant reduction in mPAP compared to those on placebo.
Intravenous Solution
A mean placebo-corrected treatment effect of -3.9 mmHg was observed in favor of sildenafil (95% CI: -5.7, -2.1) (p = 0.00003).Time to clinical worsening of PAH was defined as the time from randomization to the first occurrence of a clinical worsening event (death, lung transplantation, initiation of bosentan therapy, or clinical deterioration requiring a change in epoprostenol therapy). Table 4 displays the number of patients with clinical worsening events in PACES-1. Kaplan-Meier estimates and a stratified log-rank test demonstrated that placebo-treated patients were 3 times more likely to experience a clinical worsening event than sildenafil-treated patients and that sildenafil-treated patients experienced a significant delay in time to clinical worsening versus placebo-treated patients (p = 0.0074). Kaplan-Meier plot of time to clinical worsening is presented in Figure 5.Figure 5. Kaplan-Meier Plot of Time (in Days) to Clinical Worsening of PAH in PACES-1Improvements in WHO Functional Class for PAH were also demonstrated in patients on sildenafil compared to placebo.
© 2021 Gastroenterologie im Zentrum, Kasernenstrasse 1, 8180 Bülach, Tel 044 864 19 18, Fax 044 864 19 17